TG Therapeutics | TGTX - Operating Expenses


TG Therapeutics reported $170.12M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Amgen USD 4.78B 1.12B Mar/2026
Ardelyx USD 120.12M 14.46M Dec/2025
Arrowhead Research USD 215M 8.23M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
Corcept Therapeutics USD 214.5M 16.87M Mar/2026
Curis USD 9.02M 23.01M Dec/2025
Gilead Sciences USD 23.52B 18.55B Mar/2026
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
J&J USD 17.44B 1.53B Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Novartis USD 9.29B 507M Mar/2026
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
TG Therapeutics USD 170.12M 28.04M Mar/2026
Verastem USD 59.01M 21.98M Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026